Você está na página 1de 7

CHRONIC LYMPHOCYTIC LEUKEMIA

Novel Insights into the Biology of CLL


Mark C. Lanasa1
1Division

of Medical Oncology, Duke University Medical Center, Durham NC

Signicant advancements in the care of patients with chronic lymphocytic leukemia (CLL) have occurred over the past decade. Nonetheless, CLL remains incurable outside of allogeneic transplantation. CLL is the most common leukemia in the United States and Europe, and new treatments and therapeutic strategies are clearly needed. To address this need, the pathogenesis of CLL has been an area of intense ongoing investigation. These international efforts illuminate a complex biology that is reliant on the interplay of inherited, environmental, and host factors. This broad review will discuss the recent advances in our understanding of CLL biology including the elucidation of inherited and acquired genetic changes; the role of the B-cell receptor and B-cell receptor signaling; CLL cell kinetics; and the interactions in the microenvironment between CLL cells, other immune cells, and stromal elements. This improved understanding of disease pathogenesis is facilitating the development of novel therapeutic treatment strategies.

Chronic lymphocytic leukemia (CLL) remains an enigmatic disease. Although the rst clinical description of chronic lymphoid leukemia was published over 150 years ago, the etiology of CLL is unknown, the cell of origin of CLL is unknown, and CLL remains incurable outside of allogeneic transplantation. CLL is the most common leukemia in the United States, with approximately 15,500 new diagnoses per year. Because of the relatively long survival of patients with CLL, it is by far the most prevalent leukemia, with an estimated 95,000 Americans living with CLL.1 CLL lymphocytes have a characteristic immunophenotype: CD5, CD19, CD20dim, CD23, and surface immunoglobulindim. Although the majority of patients are asymptomatic at diagnosis, the relentless accumulation of CLL lymphocytes leads to symptomatic disease, need for CLL-directed therapy, disease-related complications, and approximately 4500 CLL attributable deaths per year in the United States. Several characteristics of CLL facilitate basic and translational research: (i) the high population prevalence; (ii) the malignant cells are easily obtained through venous phlebotomy; (iii) most patients have an asymptomatic phase that allows for longitudinal evaluation; and (iv) CLL is has a relatively long disease-specic survival. Therefore, CLL has become a model system for the investigation of B-cell lymphoproliferative disorders. In the 5 years since the biology of CLL was last broadly reviewed in the American Society of Hematology education session, tremendous progress has been made in the understanding of CLL disease biology, and this review will focus on these discoveries. Specically, important advances have been made in identifying inherited and acquired genetic mutations, the role of B-cell receptor (BCR) signaling, and the interplay between the malignant B cells and the tumor microenvironment. These advances reveal CLL to be a disease that is dependent on on the interplay of inherited, environmental, and host factors.

relatives of persons with CLL to range between 7.0 and 8.5. This equivalent risk across all rst-degree relatives suggests an inherited, rather than environmental, basis for familial CLL.4 Though families with four or more cases of CLL have been reported, they are extremely rare. Some CLL kindreds suggest a dominant inheritance, therefore, genome-wide linkage studies in familial CLL have been performed. The largest and most recent reported study added 101 new cases of familial CLL to a previously reported cohort of 105 families.5 This study was the rst statistically signicant genomewide linkage scan and identied chromosome 2q21.2 as associated with inheritance of CLL. However, no causative genes have been identied at this locus. Overall, linkage studies in CLL have been limited by the low number of affected individuals per family, late age of onset, and presumed genetic heterogeneity. Complete sequencing of the human genome revealed large numbers of common single nucleotide polymorphisms (SNPs). This discovery led to the hypothesis that the inheritance of complex diseases may be due to the coinheritance of these common variants. Di Bernardo et al6 performed a multistage genome-wide SNP association (GWA) study to evaluate the contribution of common variants to the inheritance of CLL. This study identied six novel loci associated with the development of CLL, thus providing the rst evidence for the contribution of common (population prevalence 5%) genetic variants to the development of CLL. Five of these SNPs have been validated in an independent GWA.7 Subsequently, four additional susceptibility loci have been identied through follow-up analyses from the initial Di Bernardo study.8 Identication of these genes informs our understanding of CLL biology. For example, the GWA linked interferon regulatory factor 4 (IRF4), a key regulator of lymphocyte maturation and proliferation, with risk of developing CLL. The 10 loci identied to date individually confer a small risk of disease, with relative risks ranging from 1.2 to 1.6. As a group, these risk alleles account for 10% of the total heritability of CLL. Because GWA can detect only those alleles with a population prevalence of 5%, it is possible that much of the inherited risk of CLL is due to uncommon inherited variants (prevalence 5%). Massively parallel sequencing technologies may enable the discovery of these rare variants and illuminate the hidden heritability in CLL.

Inherited Genetic Factors


The most important risk factor for the development of CLL is a family history of CLL. Among patients with newly diagnosed CLL, 8% to 10% have a family history of CLL. CLL has a heritability that is twice that of common solid tumors with known low-prevalence, high penetrance causative genes, such as breast and colon cancer.2,3 Pedigree analysis using data from the Swedish Family Cancer Database showed the relative risk of CLL among rst-degree

70

American Society of Hematology

Acquired Genetic Factors


In a landmark report by the German CLL Study Group, Dohner et al9 showed that acquired chromosomal abnormalities involving chromosomes 11, 12, 13, and 17 are common in CLL, and that these abnormalities predict both time to rst treatment and CLL-specic survival. The genes principally responsible for the adverse prognosis associated with del 17p13 and del 11q22 were recognized to be TP53 and ATM, respectively. The genes that contribute to CLL pathogenesis in trisomy 12 remain unknown. There is ongoing debate regarding whether trisomy 12 confers an increased risk of disease progression; unlike the Dohner study, our institutional experience is that patients with trisomy 12 do follow a somewhat more aggressive disease course than those patients with normal FISH (uorescence in situ hybridization).10 Deletion of 13q14 is the most common and most favorable cytogenetic abnormality in CLL. The responsible genes at this locus were initially unclear. In 2002, Calin et al11 showed that the microRNA 15/16 (miR 15/16) cluster were the critical deleted genes in this region. MicroRNAs are small (approximately 20 nucleotides) nonprotein coding RNAs that modulate the level of specic proteins by binding sequencecomplimentary mRNAs. miR-15 and miR-16 were subsequently shown to be negative regulators of BCL2.12 This discovery is notable in that it was the rst association of clinical disease with microRNAs. The Dohner study9 established interphase cytogenetics (FISH) as the clinical standard of care for evaluation of chromosomal aberrations in CLL because the low proliferative capacity of most CLL limits the clinical utility of metaphase cytogenetics. However, emerging data shows that the evaluation of four (or ve) chromosomal loci by FISH obscures the signicant heterogeneity and complexity of acquired chromosomal defects in CLL. The application of high-density SNP arrays illuminates some of this complexity. For example, copy number neutral loss of heterozygosity is observed in a signicant number of CLL cases, and this nding cannot be detected with either FISH or standard karyotyping. Using SNP arrays, Ouilette et al13 showed signicant heterogeneity among 13q14 deletions, with some deletions extending centromeric to include the retinoblastoma gene. A follow-up study showed that 13q14 deletions that include retinoblastoma are associated with genomic complexity,14 a nding associated with aggressive disease in prior clinical reports. Although data currently available are inadequate to support the widespread application of SNP arrays to routine clinical care, this technology may ultimately be a useful adjunct to routine clinical FISH. At the chromosomal level, del 17p13 is more homogenous than other acquired genomic defects. High-density SNP arrays showed that the deletion breakpoint typically falls within chromosomal band 17p11.2 and extends telomeric to include most of the p arm.15 Deletions of 17p13 are almost always monoallelic, and it was initially unclear why monoallelic loss of TP53 would cause such a dramatic change in CLL proliferative capacity, chemosensitivity, and prognosis. It is now understood that 80% of cases with del 17p13 have single nucleotide somatic mutations of the TP53 allele on the other chromosome 17 (the allele in trans), thereby causing near complete loss of TP53 function. Although uncommon, TP53 inactivating mutations can occur in the absence of del 17p13, and these mutations apparently confer an equivalent adverse risk as del 17p13.16 TP53 is a multimeric protein with four identical subunits, and these inactivating mutations may act in a dominant negative manner, thus abrogating TP53 function even in the presence of a wild-type allele in trans. Although only 5% of CLL cases show

Table 1. The mutation status of the immunoglobulin heavy chain (IGVH) as a central determinant of CLL biology
IGVH Unmutated Cell of origin Mature (antigen experienced) B cell Postulated mechanism of maturation Chromosomal abnormalities Frequency of BCR stereotypy Antigen recognition Response to BCR cross-linking Germinal center, T-help dependent del 11q22, del 17p13 40% Polyreactive Activation, proliferation IGVH Mutated Mature (antigen experienced) B cell T-help independent, germinal center independent (?) del 13q14 (sole) 10% oligoreactive Anergy or no response

deletion or mutation of 17p13 at diagnosis, somatic mutations occur in approximately one-third of relapsed or chemotherapy refractory patients. Whether this represents clonal selection or clonal evolution or both is an area of active investigation. Epigenetic changes are also relevant to the pathogenesis of CLL. Epigenetic changes are noninherited chromosomal modications that affect gene transcription, such as methylation of gene promoters and acetylation of histone-bound DNA. An example of epigenetic change, global hypomethylation of DNA, has been described in CLL. Between 2% and 8% of CpG islands (gene promoter elements) are aberrantly methylated in CLL when compared with normal B cells, a nding that suggests DNA methylation broadly affects the transcriptional prole of CLL. A germline mutation in death-associated protein kinase 1 (DAPK1) that segregated with risk of CLL was identied by Raval et al18 in a family with multiple CLL cases. The authors showed that DAPK1 expression is silenced through promoter methylation in the majority of CLL cases, suggesting a central role for both epigenetic modication and DAPK1 in CLL leukemogenesis.18 Using high-density methylation microarrays evaluating over 27,000 CpG sites, Kanduri et al19 identied differential patterns of methylation that were dependent on the mutation status of the BCR. Poor-risk CLL showed methylation proles that facilitated signaling through proliferative cellular pathways, including MAPK (mitogen-activated protein kinase) and NF-B (nuclear factor- light-chain enhancer of activated B cells), a nding that directly relates the clinical phenotype of poor-risk CLL to methylation of BCR-mediated signaling pathways.

The Role of BCR in CLL


Investigation of the immunoglobulin gene has led to ndings that are central to the current understanding of CLL (Table 1). During B-cell development, variable-diversity-joining (VDJ) recombination generates an immunoglobulin heavy chain (IGH), and an immunoglobulin light chain (IGL) is created through isotypespecic VJ recombination. There is tremendous combinatorial potential in this process, with perhaps 1010 potential IGH-IGL sequence combinations. However, patients with CLL use a highly restricted set of BCRs.20 Approximately 14% of all CLL cases express the heavy chain VH1 69, and an additional 18% express VH4 34. This nding of marked restriction of the IGH repertoire led to the hypothesis that tonic stimulation by specic auto or alloantigens drives expansion of the malignant clone.21,22 Intraclonal diversication of some CLL further supports the antigendrive hypothesis.23 During the germinal center reaction, somatic mutations are generated in the BCR to increase afnity for target antigen. Approximately half of CLL cases show IGH mutations, and the other half

Hematology 2010

71

show an unmutated IGH, typically dened as 2% deviation from germline sequence. Patients with mutated IGH typically follow a more indolent disease course than those with unmutated IGH24. This initially led to the hypothesis that CLL may be two distinct entities, one deriving from naive (IGH unmutated) B cells and the other from postgerminal center memory (IGH mutated) B cells. However, gene expression proling studies in CLL show both IGH mutated and unmutated CLL to be derived from memory B cells.25,26 The mechanism by which some CLL escape IGH mutation is unclear. One hypothesis proposes that certain antigens favor a helper T-cell independent or germinal center independent maturation that does not involve IGH mutation. Alternatively, the IGH unmutated CLL cells may be autoreactive and targeted for apoptosis, but avoid cell death through either tonic BCR stimulation or transforming genetic events. Recent experiments using phage display libraries have attempted to better dene the types of antigens and epitopes recognized by IGH mutated and unmutated CLL. Monoclonal antibodies (MAbs) generated from the BCR of IGH-mutated CLL bound epitopes with structurally related amino acid motifs, whereas unmutated CLL recognized multiple different epitopes.27 This suggests that in vivo multiple, potentially structurally divergent antigens can bind and stimulate CLL cells through the BCR. This conclusion is provocative because six of eight of the CLL MAbs investigated had stereotyped BCRs. Stereotypy is the observation of near complete sequence homology of the complimentarity-determining region 3 (CDR3) of the IGH28; the CDR3 largely denes the antigen specicity of the BCR. For example, approximately 1% of all CLL express VH1 69 that are virtually identical within the CDR3.29 The presence of a stereotyped BCR is associated with adverse risk, independent of IGH mutation status, although stereotypy is more commonly observed among unmutated (40%) than mutated CLL (10%). The observation of stereotypy has been forwarded as evidence of selective antigenic pressure in CLL; however, MAbs derived from these BCRs may be oligo- or polyreactive in vivo. MAbs derived from stereotyped BCRs have also been shown to react with conserved epitopes exposed on apoptotic cells.30 The selection of stereotyped BCRs may be related to a combination of antigenic pressure and CDR3 sequence facilitated BCR signaling. Given the clear importance of the BCR in the clinical behavior of CLL, the role of BCR-mediated signaling is another area of signicant interest. The surface density of the BCR is lower in CLL than in most B-cell subsets, suggesting CLL may have attenuated signaling responses to antigen binding. Experimental evidence shows that, in vitro, approximately half of all CLL retain BCRmediated signaling, and that the IGH mutation status and other molecular characteristics used for clinical prognostication (eg, CD38 and ZAP70 [zeta-associated protein 70]) are important determinants of BCR responsiveness. After cross-linking the BCRs with isotype-specic antibodies, Lanham et al31 showed global increases in tyrosine phosphorylation, a marker of induction of intracellular signaling. The responsiveness to cross-linking was strongly associated with IGH mutation status (P .0005), as well as expression of CD38 (P .05).31 Using gene expression proling, Guarini et al32 showed that BCR cross-linking with anti-IgM led to the transcription of gene pathways regulating cell-cycle regulation, cytoskeletal organization, and proliferation; but, these changes were only observed among IGH unmutated cases. BCR ligation leads to enhanced intracellular signaling among ZAP70 expressing CLL, and the introduction of ZAP70 into CLL not otherwise expressing ZAP70 augments BCR-mediated signaling, suggesting a direct role

for ZAP70 in BCR-mediated signaling.33 Muzio et al34 showed that CLL B cells that do not respond to BCR ligation (typically IGH-mutated cases) show activation of cellular pathways that suggest anergy. BCR signaling in vivo is likely even more complicated: assuming that there are multiple antigens capable of binding the BCR, the binding afnity for a specic antigen likely determines whether the response is activating or anergic. Although this complexity in vivo remains incompletely understood, in general, BCR ligation in IGH unmutated CLL leads to predominantly activating and proliferative responses, whereas BCR signaling in IGH-mutated CLL favors anergic and antiapoptotic responses. Additionally, the adverse risk associated with ZAP70 and CD38 expression may be directly related to their effects on cell signaling and activation.

CLL Cell Kinetics


The conventional view of CLL had been that it is primarily a disease of failed apoptosis and passive accumulation. This view is supported by the observation that the great majority ( 98%) of peripherally circulating CLL cells are arrested in G0 or the early G1 phase and have overexpression of antiapoptotic proteins, such as BCL2. Other observations suggest that CLL may have signicant proliferative capacity. As discussed in the prior section, IGH unmutated CLL has the capacity for proliferative responses to BCR ligation. Many CLL express markers of cellular activation (eg, CD38, CD49d, and CD69), providing a link between CLL cell biology and prognostics. Clonal evolution and Richters transformation are observed in some cases. In a series of elegant experiments, Messmer et al 35 evaluated the in vivo kinetics of CLL by having patients consume xed doses of deuterated heavy water (2H2O) for 84 days. The deuterium was incorporated into newly synthesized DNA during the S phase. Using mass spectrometry, the birth and death rates of CLL cells were then determined. Although there was signicant variability in birth rates (0.11%1.76%/day), all patients had a rate of new cell formation of at least 109 new CLL cells per day. Patients with higher birth rates (exceeding 0.35%/day) were more likely to have symptomatic disease. Signicant variability was also observed in the cellular death rate, and the balance between birth and death likely determines both white blood cell trend and risk of progression.35 The deuterated water experiments also provided novel insights into CLL intraclonal heterogeneity and CLL cell trafcking. By ow sorting the CD38 and CD38 fractions from CLL patients receiving deuterated water, Calissano et al36 showed that the CD38 fraction proliferated at a greater rate than the CD38 fraction. It has previously been shown that, regardless of the proportion of CD38 cells, these cells show signicantly increased expression of proliferation factors ZAP70, Ki67, and telomerase when compared with the CD38 fraction.37 In a more recent report, Calissano et al provided preliminary evidence that new CLL cells have a distinct immunophenotype: CD5hiCXCR4low, whereas resting CLL cells are CD5lowCXCR4hi. Gene expression array analysis of ow sorted new and resting cell fractions that showed that new cells differentially express genes related to proliferation, cellular activation, and cell signaling, whereas resting cells predominantly express genes involved in apoptosis, cell death, and migration.38 These studies have led to the hypothesis that CLL cells in the blood compartment eventually enter a pathway of cellular senescence. Upregulation of CXCR4 (a CXC chemokine receptor) promotes reentry into the tumor microenvironment, where the cells receive prosurvival signals. Rather than undergoing apoptosis, a subset of resting CLL cells are activated, proliferate, downregulate CXCR4,

72

American Society of Hematology

and are then released back into the peripheral blood. These studies shed light on the phenotypic continuum of CLL cells and better dene the life cycle of a CLL B cell, as well as the central role of the tumor microenvironment in maintaining the malignant clone.

The Tumor Microenvironment in CLL


Over the past decade, the essential role of the tumor microenvironment in the survival and progression of CLL has become increasingly clear. The tumor microenvironment describes an admixture of malignant cells with host immune cells, stromal elements, and vascular cells that create a niche wherein signals can be transmitted through antigen presentation, cell cell interactions, and paracrine signaling. The microenvironments differ in the bone marrow and secondary lymphoid organs, where the former contains mesenchymal stromal cells (MSC) within vascular niches and in the latter nurse-like cells (NLCs), T cells and follicular dendritic cells are present. NLCs are large CD14 mononuclear cells that are abundant in the secondary lymphoid organs of patients with CLL.39 NLCs and MSCs constitutively express the chemokines CXCL12 (stromalderived factor-1, Sdf-1) and CXCL13. CLL cells express CXCR4 (CD184), the receptor for Sdf-1, and in vitro studies have shown that engagement of Sdf-1 with CXCR4 promotes cell survival through activation of the signal transducer and activator of transcription 3 (STAT3) and MAPK pathways. Blockade of this interaction with a small molecule inhibitor leads to decreased CLL viability, suggesting this interaction is a potential therapeutic target.40 Additional studies have shown that CLL cell viability can be signicantly enhanced in vitro with Sdf-1, although viability is further enhanced with NLCs over Sdf-1, suggesting that NLCs also deliver additional prosurvival signals. It is now understood that, in addition to Sdf-1, NLCs also secrete B-cell activating factor (BAFF) and a proliferationinducing ligand (APRIL). Engagement of these ligands with CLL cells induces intracellular NF-B1 and MCL-1, whereas sdf-1 induces ERK1/2 and AKT. As such, NLCs can deliver multiple prosurvival signals that utilize distinct signaling pathways.41 Engagement of CD40, expressed on the surface of CLL cells, with CD154 (CD40L), expressed on CD4 T cells found in CLL pseudofollicles, also induces the NF-B pathway. These diverse interactions have important implications for CLL therapy, particularly as mechanisms of chemotherapy resistance. A recent report showed that in vitro coculture of CLL cells with CD154 expressing broblasts induced 1000-fold resistance to ABT-737, a small molecular inhibitor of BCL2 and BCL-XL.42 Similarly, coculture of CLL cells with MSCs induces resistance to udarabine, cyclophosphamide, and dexamethasone through maintenance of MCL-1.43 Taken together, these in vitro data strongly suggest that the tumor microenvironment enhances CLL cell resistance to both apoptosis and chemotherapy. Investigation of novel mechanisms of interaction between the tumor microenvironment and CLL cells is an active area of research. CLL cells have the capacity to affect local angiogenesis within the vascular niche. Microvessel density is increased in bone marrow of CLL patients, with highest densities found at the periphery of lymphoid aggregates. CLL cells have the capacity to secrete a variety of angiogenic cytokines, including vascular endothelial growth factor (VEGF), basic broblast growth factor (bFGF), and thrombospondin-1 (TSP-1).44 More recently, Ghosh et al45 described the contribution of CLL cell-derived microvesicles as a mechanism by which CLL cells can module the local microenvironment. Microvesicles are cell membrane-derived particles that can deliver cell surface receptors, activated signaling proteins, or nucleic

acids to target cells. The authors found that CLL cell-derived microvesicles were increased in patients with advanced-stage CLL, and that microvesicles could activate AKT/mTOR signaling in MSCs.45 Thus, microvesicles represent a novel mechanism of CLL signaling within the microenvironment. Finally, toll-like receptors (TLRs) are cell surface receptors that are part of the innate immune system that bind structurally conserved microbial antigens and activate immune responses. Recent data shows that TLRs are expressed and functional in CLL; binding of TLRs with cognate antigen-activated NF-B expression and induced surface expression of activation markers CD25 and CD80.46 Given the architectural complexity, number of different cell types present, and clinical importance of these interactions, investigation of the tumor microenvironment will continue to be an active and fruitful area of research in CLL.

T-Cell Abnormalities in CLL


Most malignancies are associated with decreased numbers of circulating T cells, but in CLL they are elevated 2.5 to 4 times normal, at least pretherapy.47 Although T cells are increased in number, the T-cell repertoire is signicantly contracted in CLL, with oligoclonal and monoclonal subsets.48,49 CLL cells secrete immunomodulatory cytokines, such as interleukin-6, interleukin10, and tumor growth factor- (TGF-), which shift the helper T-cell response from a Th1 response to an anergic Th2 response.50,51 Suppressive regulatory T cells (Treg) are also increased in patients with CLL.52 A mechanism for this increase may be direct CLLTcell contact through CD27 and CD70; this interaction also induces BCL2 within the Treg, making the Treg cell population in CLL patients more resistant to apoptosis than in normal individuals.53 These qualitative and quantitative T-cell abnormalities likely allow the CLL lymphocytes to avoid cell-mediated immune responses, despite the fact that CLL cells express tumor-specic antigens that can be presented by major histocompatibility complex molecules. To better understand the mechanism underlying impaired T-cell responses in CLL, Gorgun et al54 performed gene expression array analyses of puried CD4 and CD8 T cells. Among CD4 T cells, genes related to cell differentiation were differentially expressed between T cells derived from previously untreated CLL patients and healthy controls. Gene pathways controlling cytoskeleton formation, vesicle trafcking, and cytotoxicity were differentially expressed in CD8 T cells. When CLL cells were cocultured with CD4 or CD8 T cells obtained from healthy controls, the abnormal patterns of gene expression were induced, suggesting that these T-cell defects are due to direct cell cell contact.54 In light of the observed dysregulation of cytoskeleton assembly genes, a subsequent study by Ramsay et al55 evaluated the capacity of T cells to form a normal immunological synapse. This study showed that T cells derived from CLL patients could not form normal cell cell contact and that recruitment of T-cell signaling proteins to the synapse was blocked. Similarly, coculture of CLL cells with donor T cells blocked the formation of an immunologic synapse.55 The inability of T cells derived from CLL patients to form a normal immunologic synapse likely impairs both antigen recognition and cellular cytotoxicity. Taken together, this global impairment in T-cell function may be an important cause of tumor progression, increased susceptibility to infection, and secondary malignancies in patients with CLL.

Using Novel Biologic Insights to Develop an Integrated Model of Disease Biology


Detailed laboratory-based and translational investigation has yielded tremendous progress in our understanding of CLL. One of the

Hematology 2010

73

signicant challenges at this time is to assemble this body of knowledge into a unied model of disease pathogenesis. Epidemiologic data implies the importance of ethnicity (likely a marker of genetic risk) and age (a marker of immune senescence). A proposed model follows: in a genetically susceptible host, tonic stimulation by a stereotyped antigenlikely a low-afnity autoantigen initiates expansion of a premalignant clone. Through some combination of tonic antigenic stimulation, acquisition of somatic genetic mutations, and timely support from the tumor microenvironment, the potentially autoreactive clone escapes immune surveillance and begins to expand. In the tumor microenvironment, cells receive proliferative signals from CD4 T cells and antiapoptotic signals from NLCs and MSCs. Initially supported by the tumor microenvironment, the increasing clone may begin to further modulate the microenvironment and immune response to favor survival and progression of the clone. Among IGH unmutated clones, BCRtransmitted signals provide predominantly proliferative signals, whereas IGH-mutated clones express gene pathways related to cellular anergy. The CLL cells continue to receive antigenic stimulation, and as the clone continues to proliferate, additional somatic mutations are acquired, and this may diminish the reliance of the clone on both antigenic stimulation and microenvironment support. Some central questions to be investigated include the molecular basis of the 2:1 male:female gender bias in CLL, the mechanism by which some CLL acquire somatic mutations and others do not (ie, the molecular determinants of IGH mutation status), the mechanism by which preemergent CLL clones escape immune surveillance and deletion, and whether clonal evolution can be avoided through suppression of the proliferative compartment of CLL. Finally, this scientic progress has created numerous targets of novel therapeutic interventions. Lineage-restricted cell surface molecules, such as ROR1 and CD37, are targets of novel MAbs. Lenalidomide has been shown to reverse the abnormal immunologic synapse formation in CLL, and also modulates the microenvironment through monocyte and NK cell activation. Novel small molecule inhibitors of BCR-mediated signaling are currently being tested in clinical trials. CAL101 selectively blocks a phosphatidylinositol 3-kinase isoform related to downstream signaling from CXCR4. Additional trials studying small molecular inhibitors of antiapoptotic proteins, such as BCL2, are underway. Elucidation of the mechanisms of chemotherapy resistance related to loss of p53 function has led to strategies to circumvent p53-dependent pathways. The advances in our fundamental understanding of the mechanisms of disease in CLL will undoubtedly lead to improved therapies for our patients.

References
1. Altekruse SF, Krapcho M, Neyman N, et al. SEER cancer statistics review, 19752007. SEER Web site. http://seer.cancer. gov/csr/1975_2007/ (based on November 2009 SEER data submission, posted to the SEER web site, 2010). Accessed May 1, 2010. 2. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 2004;1:e65. 3. Kerber RA, OBrien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer. 2005;103:1906 1915. 4. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish FamilyCancer Database. Blood. 2004;104:1850 1854. 5. Sellick GS, Wild RW, Slager SL, et al. A high-density SNP genome-wide linkage search of 206 families identies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007;110: 3326 3333. 6. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10): 1204 1210. 7. Slager SL, Goldin LR, Strom SS, et al. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2010;19:1098 1102. 8. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 inuence chronic lymphocytic leukemia risk. Nat Genet. 2010; 42:132136. 9. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910 1916. 10. Weinberg JB, Volkheimer AD, Chen Y, et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. Am J Hematol. 2007;82:10631070. 11. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524 15529. 12. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102:13944 13949. 13. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic proling of chronic lymphocytic leukemia identies subtypes of deletion 13q14. Cancer Res. 2008;68:10121021. 14. Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res. 2010;16:835 847. 15. Fabris S, Mosca L, Todoerti K, et al. Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2008;47:781 793. 16. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:33223329. 17. Rush LJ, Raval A, Funchain P, et al. Epigenetic proling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004;64:2424 2433.

Disclosures
Conict-of-interest disclosure: The author has consulted and been afliated with the Speakers Bureau for GlaxoSmithKline and Genentech, and has received research funding from Celgene and Eleos. Off-label drug use: None disclosed.

Correspondence
Mark C. Lanasa, MD, PhD, Assistant Professor of Medicine, Division of Medical Oncology, Duke University Medical Center, DUMC Box 3872, 1 Trent Dr., Morris Building Room 25153, Durham, NC 27710; Phone: (919) 684-8964; Fax: (919) 684-5325; e-mail: mark.lanasa@duke.edu

74

American Society of Hematology

18. Raval A, Tanner SM, Byrd JC, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007;129:879 890. 19. Kanduri M, Cahill N, Goransson H, et al. Differential genomewide array-based methylation proles in prognostic subsets of chronic lymphocytic leukemia. Blood. 2010;115:296 305. 20. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:15151525. 21. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood. 2004;104:2879 2885. 22. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519 525. 23. Volkheimer AD, Weinberg JB, Beasley BE, et al. Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intraclonal diversication. Blood. 2007;109:1559 1567. 24. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94: 1848 1854. 25. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194: 1639 1647. 26. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression proling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194: 16251638. 27. Seiler T, Woele M, Yancopoulos S, et al. Characterization of structurally dened epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood. 2009;114:36153624. 28. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111:1524 1533. 29. Widhopf GF 2nd, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood. 2004;104:2499 2504. 30. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115:39073915. 31. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:10871093. 32. Guarini A, Chiaretti S, Tavolaro S, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782792. 33. Chen L, Huynh L, Apgar J, et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2008;111:26852692. 34. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation

35.

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112(1):188 195. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755 764. Calissano C, Damle RN, Hayes G, et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood. 2009;114:4832 4842. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 2007;110:3352 3359. Calissano C, Yan XJ, et al. Multi-parameter phenotypic analysis of members of chronic lymphocytic leukemia clones identies distinct proliferative and resting/re-Entry compartments with discrete gene expression proles [abstract 668]. Blood. 2009;114. Burger JA, Tsukada N, Burger M, Zvaier NJ, DellAquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:26552663. Burger M, Hartmann T, Krome M, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005;106:1824 1830. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005;106:10121020. Vogler M, Butterworth M, Majid A, et al. Concurrent upregulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403 4413. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and druginduced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114:4441 4450. Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and antiangiogenic molecules. Leukemia. 2002;16:911919. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115:17551764. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507516. Markey GM, Alexander HD, Agnew AN, et al. Enumeration of absolute numbers of T lymphocyte subsets in B-chronic lymphocytic leukaemia using an immunoperoxidase technique: relation to clinical stage. Br J Haematol. 1986;62:257273. Goolsby CL, Kuchnio M, Finn WG, Peterson L. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3()CD8() T-cell population. Cytometry. 2000;42:188 195. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4CD57 and CD8CD57 T cell subsets in chronic lymphocytic leukemia. J Immunol. 1997;158:14821489.

Hematology 2010

75

50. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med. 1994;179:999 1004. 51. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256 263. 52. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with udarabine. Blood. 2005;106:2018 2025.

53. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4 CD25hi Foxp3 T-cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:788 801. 54. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115: 17971805. 55. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:24272437.

76

American Society of Hematology

Você também pode gostar